Golimumab (optimization) (DrugBank: Golimumab)
6 diseases| 告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 0 |
| 56 | ベーチェット病 | 0 |
| 84 | サルコイドーシス | 0 |
| 96 | クローン病 | 0 |
| 97 | 潰瘍性大腸炎 | 1 |
| 271 | 強直性脊椎炎 | 0 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03182166 (ClinicalTrials.gov) | November 21, 2017 | 29/5/2017 | Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization | Pharmacokinetic and Pharmacodynamic Study of Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization | Ulcerative Colitis | Drug: Golimumab (Optimization);Diagnostic Test: Rectosigmoidoscopy;Biological: Blood samples | Centre Hospitalier Universitaire de Saint Etienne | Merck Sharp & Dohme Corp. | Recruiting | 18 Years | N/A | All | 80 | Phase 2 | France |